Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects.

Blase E, Taylor K, Gao HY, Wintle M, Fineman M

Journal of clinical pharmacology1 May 2005Cited by 63 (Europe PMC)

PMID15831781DOI10.1177/0091270004274432PepBankPUB-15831781

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialPharmacokinetics
In healthy subjects, exenatide reduced acetaminophen AUC by 11% to 24% versus placebo.
In plain wordsExenatide reduced total acetaminophen exposure by 11% to 24% compared with placebo in healthy subjects.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseAcetaminophen AUC
Study
n = 39
Comparator
Placebo
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
10 mug · subcutaneousAs given in this study (human).
Measurements
Reduction in acetaminophen AUC(0-12 h)
11 to 24%
exenatide 10 mug vs placebo, mean plasma values
Source sentences
Summary
With exenatide injection, mean plasma acetaminophen AUC(0-12 h) values were reduced by 11% to 24% (vs placebo).
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized, single-blind, placebo-controlled 6-way crossover study assessed exenatide's effect on acetaminophen pharmacokinetics.
Summary · context
On exenatide days, acetaminophen was ingested at -1, 0, +1, +2, and +4 hours, relative to the 10 mug exenatide injected subcutaneously at 0 hours.
Report a problemFND-1583178101
02HumanRandomized controlled trialPharmacokinetics
In healthy subjects, acetaminophen peak concentrations were similar with ingestion before exenatide and with placebo.
In plain wordsAcetaminophen peak levels were similar when taken before exenatide and with placebo in healthy subjects.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeAcetaminophen peak concentration before exenatide
Study
n = 39
Comparator
Placebo
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
10 mug · subcutaneousAs given in this study (human).
Source sentences
Summary
Peak plasma acetaminophen concentrations were similar for the -1-hour and placebo groups and reduced by 37% to 56% at other times.
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized, single-blind, placebo-controlled 6-way crossover study assessed exenatide's effect on acetaminophen pharmacokinetics.
Summary · context
On exenatide days, acetaminophen was ingested at -1, 0, +1, +2, and +4 hours, relative to the 10 mug exenatide injected subcutaneously at 0 hours.
Report a problemFND-1583178102
03HumanRandomized controlled trialPharmacokinetics
In healthy subjects, acetaminophen peak concentrations fell by 37% to 56% with ingestion at or after exenatide versus placebo.
In plain wordsAcetaminophen peak levels fell by 37% to 56% when taken with or after exenatide compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseAcetaminophen peak concentration with or after exenatide
Study
n = 39
Comparator
Placebo
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
10 mug · subcutaneousAs given in this study (human).
Measurements
Reduction in peak plasma acetaminophen concentration
37 to 56%
acetaminophen at 0, +1, +2, +4 h relative to exenatide vs placebo
Source sentences
Summary
Peak plasma acetaminophen concentrations were similar for the -1-hour and placebo groups and reduced by 37% to 56% at other times.
2 context sentences(design, population, supporting numbers)
Summary · context
On exenatide days, acetaminophen was ingested at -1, 0, +1, +2, and +4 hours, relative to the 10 mug exenatide injected subcutaneously at 0 hours.
Summary · context
This randomized, single-blind, placebo-controlled 6-way crossover study assessed exenatide's effect on acetaminophen pharmacokinetics.
Report a problemFND-1583178103

Studies that did not test the peptide alone2

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

04HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialSafety outcome
In healthy subjects studied with acetaminophen and exenatide or placebo, generally mild to moderate nausea was among the most frequent adverse events.
In plain wordsIn healthy subjects studied with acetaminophen and exenatide or placebo, nausea was frequent and generally mild to moderate.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableNausea
Study
n = 39
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
The most frequent adverse events were generally mild to moderate nausea and vomiting.
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized, single-blind, placebo-controlled 6-way crossover study assessed exenatide's effect on acetaminophen pharmacokinetics.
Summary · context
On exenatide days, acetaminophen was ingested at -1, 0, +1, +2, and +4 hours, relative to the 10 mug exenatide injected subcutaneously at 0 hours.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1583178104
05HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialSafety outcome
In healthy subjects studied with acetaminophen and exenatide or placebo, generally mild to moderate vomiting was among the most frequent adverse events.
In plain wordsIn healthy subjects studied with acetaminophen and exenatide or placebo, vomiting was frequent and generally mild to moderate.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableVomiting
Study
n = 39
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
The most frequent adverse events were generally mild to moderate nausea and vomiting.
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized, single-blind, placebo-controlled 6-way crossover study assessed exenatide's effect on acetaminophen pharmacokinetics.
Summary · context
On exenatide days, acetaminophen was ingested at -1, 0, +1, +2, and +4 hours, relative to the 10 mug exenatide injected subcutaneously at 0 hours.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1583178105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.